Amneal Gross Profit from 2010 to 2024

AMRX Stock

USD 8.32 0.09 1.07%

Amneal Pharmaceuticals, Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 675.9 M in 2024. Gross Profit is the profit Amneal Pharmaceuticals, Class makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2016-12-31

Previous Quarter

249.9 M

Current Value

269.6 M

Quarterly Volatility

49.1 M

Covid

Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.

Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Amneal Pharmaceuticals, Class over the last few years. Gross profit is a required income statement account that reflects total revenue of Amneal Pharmaceuticals, Class minus its cost of goods sold. It is profit before Amneal Pharmaceuticals, operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Amneal Pharmaceuticals,'s Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 791.46 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Amneal Gross Profit Regression Statistics

	Arithmetic Mean	574,597,768
	Geometric Mean	556,826,993
	Coefficient Of Variation	25.96
	Mean Deviation	129,361,486
	Median	526,178,000
	Standard Deviation	149,146,826
	Sample Variance	22244.8T
	Range	467.6M
	R-Value	0.76
	Mean Square Error	10009.6T
	R-Squared	0.58
	Significance	0.0009
	Slope	25,446,181
	Total Sum of Squares	311426.9T

Amneal Gross Profit History

	2024	675.9 M
	2023	820.6 M
	2022	784.7 M
	2021	769 M
	2020	628.4 M
	2019	353 M
	2018	716.4 M

Other Fundumenentals of Amneal Pharmaceuticals,

Gross Profit Margin

Amneal Pharmaceuticals, Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.88	-0.95	0.89	-0.28	0.69	0.91	0.84	0.93	-0.78	0.93	0.65	0.94	0.32	0.92	0.24	0.37	0.96	0.86	0.73	0.6	0.96	0.85	0.25	-0.21
Total Stockholder Equity	0.88		-0.85	0.73	0.1	0.82	0.79	0.63	0.74	-0.64	0.8	0.33	0.8	0.02	0.76	-0.01	0.06	0.93	0.67	0.65	0.25	0.84	0.79	0.04	0.01
Net Tangible Assets	-0.95	-0.85		-0.96	0.43	-0.74	-0.98	-0.91	-0.94	0.9	-0.97	-0.71	-0.99	-0.43	-0.96	-0.29	-0.48	-0.99	-0.93	-0.87	-0.68	-0.99	-0.87	-0.34	0.3
Net Debt	0.89	0.73	-0.96		-0.57	0.62	0.99	0.94	0.95	-0.96	0.97	0.81	0.98	0.53	0.96	0.35	0.58	0.92	0.92	0.91	0.72	0.95	0.8	0.33	-0.3
Retained Earnings	-0.28	0.1	0.43	-0.57		-0.02	-0.5	-0.64	-0.52	0.6	-0.49	-0.81	-0.49	-0.81	-0.5	-0.63	-0.83	-0.27	-0.61	-0.55	-0.85	-0.42	-0.23	-0.58	0.6
Accounts Payable	0.69	0.82	-0.74	0.62	-0.02		0.65	0.45	0.52	-0.59	0.65	0.2	0.63	0.08	0.52	0.03	0.11	0.8	0.58	0.67	0.18	0.67	0.51	0.12	-0.09
Long Term Debt	0.91	0.79	-0.98	0.99	-0.5	0.65		0.95	0.95	-0.95	0.98	0.78	0.99	0.48	0.98	0.31	0.53	0.95	0.92	0.92	0.7	0.97	0.85	0.33	-0.29
Net Receivables	0.84	0.63	-0.91	0.94	-0.64	0.45	0.95		0.96	-0.9	0.95	0.88	0.96	0.55	0.97	0.37	0.6	0.85	0.91	0.85	0.84	0.92	0.8	0.39	-0.33
Good Will	0.93	0.74	-0.94	0.95	-0.52	0.52	0.95	0.96		-0.84	0.98	0.86	0.98	0.51	0.98	0.42	0.57	0.9	0.92	0.79	0.78	0.96	0.81	0.34	-0.32
Short Term Investments	-0.78	-0.64	0.9	-0.96	0.6	-0.59	-0.95	-0.9	-0.84		-0.89	-0.73	-0.91	-0.5	-0.9	-0.26	-0.55	-0.84	-0.85	-0.95	-0.69	-0.87	-0.78	-0.33	0.28
Long Term Debt Total	0.93	0.8	-0.97	0.97	-0.49	0.65	0.98	0.95	0.98	-0.89		0.82	0.99	0.49	0.98	0.41	0.54	0.95	0.93	0.88	0.72	0.97	0.81	0.32	-0.31
Capital Surpluse	0.65	0.33	-0.71	0.81	-0.81	0.2	0.78	0.88	0.86	-0.73	0.82		0.8	0.77	0.82	0.71	0.81	0.61	0.82	0.72	0.87	0.73	0.51	0.45	-0.51
Total Liab	0.94	0.8	-0.99	0.98	-0.49	0.63	0.99	0.96	0.98	-0.91	0.99	0.8		0.49	0.99	0.35	0.54	0.96	0.94	0.87	0.73	0.99	0.86	0.35	-0.31
Short Long Term Debt	0.32	0.02	-0.43	0.53	-0.81	0.08	0.48	0.55	0.51	-0.5	0.49	0.77	0.49		0.5	0.88	1.0	0.3	0.69	0.52	0.68	0.46	0.24	0.81	-0.88
Total Current Assets	0.92	0.76	-0.96	0.96	-0.5	0.52	0.98	0.97	0.98	-0.9	0.98	0.82	0.99	0.5		0.35	0.55	0.92	0.93	0.84	0.76	0.97	0.89	0.36	-0.32
Treasury Stock	0.24	-0.01	-0.29	0.35	-0.63	0.03	0.31	0.37	0.42	-0.26	0.41	0.71	0.35	0.88	0.35		0.87	0.2	0.53	0.35	0.55	0.32	0.05	0.61	-0.8
Short Term Debt	0.37	0.06	-0.48	0.58	-0.83	0.11	0.53	0.6	0.57	-0.55	0.54	0.81	0.54	1.0	0.55	0.87		0.36	0.74	0.55	0.73	0.51	0.3	0.81	-0.87
Intangible Assets	0.96	0.93	-0.99	0.92	-0.27	0.8	0.95	0.85	0.9	-0.84	0.95	0.61	0.96	0.3	0.92	0.2	0.36		0.88	0.82	0.57	0.97	0.87	0.26	-0.2
Common Stock	0.86	0.67	-0.93	0.92	-0.61	0.58	0.92	0.91	0.92	-0.85	0.93	0.82	0.94	0.69	0.93	0.53	0.74	0.88		0.82	0.81	0.95	0.81	0.64	-0.6
Property Plant Equipment	0.73	0.65	-0.87	0.91	-0.55	0.67	0.92	0.85	0.79	-0.95	0.88	0.72	0.87	0.52	0.84	0.35	0.55	0.82	0.82		0.61	0.82	0.68	0.33	-0.32
Current Deferred Revenue	0.6	0.25	-0.68	0.72	-0.85	0.18	0.7	0.84	0.78	-0.69	0.72	0.87	0.73	0.68	0.76	0.55	0.73	0.57	0.81	0.61		0.71	0.6	0.59	-0.56
Net Invested Capital	0.96	0.84	-0.99	0.95	-0.42	0.67	0.97	0.92	0.96	-0.87	0.97	0.73	0.99	0.46	0.97	0.32	0.51	0.97	0.95	0.82	0.71		0.9	0.41	-0.35
Net Working Capital	0.85	0.79	-0.87	0.8	-0.23	0.51	0.85	0.8	0.81	-0.78	0.81	0.51	0.86	0.24	0.89	0.05	0.3	0.87	0.81	0.68	0.6	0.9		0.35	-0.22
Capital Stock	0.25	0.04	-0.34	0.33	-0.58	0.12	0.33	0.39	0.34	-0.33	0.32	0.45	0.35	0.81	0.36	0.61	0.81	0.26	0.64	0.33	0.59	0.41	0.35		-0.96
Long Term Investments	-0.21	0.01	0.3	-0.3	0.6	-0.09	-0.29	-0.33	-0.32	0.28	-0.31	-0.51	-0.31	-0.88	-0.32	-0.8	-0.87	-0.2	-0.6	-0.32	-0.56	-0.35	-0.22	-0.96

Click cells to compare fundamentals

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	820.6 M	675.9 M
Gross Profit Margin	0.34	0.47

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC